Trade SYRE stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Spyre Therapeutics, Inc. (SYRE) is trading at US$90.25, down 2.62% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$9.39B. Over the past 52 weeks, SYRE has traded between US$14.51 and US$110.18. On Syfe you can trade SYRE with $0 commission and add it to your watchlist.
| Previous close | US$92.68 |
|---|---|
| Market cap | US$9.39B |
| 52-week range | US$14.51 – US$110.18 |
| Volume | 3.35M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Year: 2016
Spyre Therapeutics, Inc. (SYRE) stock is trading at US$90.25, -2.62% from the previous close of US$92.68.
The market cap for Spyre Therapeutics, Inc. (SYRE) stock is approximately US$9.39B.
The 52-week high for Spyre Therapeutics, Inc. (SYRE) stock is US$110.18.
The 52-week low for Spyre Therapeutics, Inc. (SYRE) stock is US$14.51.
Spyre Therapeutics, Inc. (SYRE) does not currently pay a dividend.
Stay on top of SYRE
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
